Purchase this article with an account.
N. Salazar-Teran, V. Kon-Jara, O. Ustariz-Gonzalez, E. Reyna-Castelan, J. Fromow-Guerra, H. Quiroz-Mercado; Does Avastin Change Evolution in Juxtafoveal Telangiectasias?. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4142.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate efficacy of intravitreal injection of Bevacizumab (2.5 mg/0.1 ml) in patients with Juxtafoveal Telangiectasias (JT) secondary to Branch Retinal Vein Occlusion (TBRVO) and Idiopathic Retinal Telangiectasias (IJRT) and to compare results in both groups.
Retrospective, non-randomized, comparative and descriptive open-label study of 11 eyes (9 patients) with JT that were injected with Intravitreal Bevacizumab (Avastin) 2.5 mg/0.1ml. A standardized ophthalmic evaluation was performed at baseline and at 1 and 3 months (±1). Main outcome measures included ETDRS best corrected Visual Acuity (BCVA) at baseline, and after 1 and 3 months respectively; Optical Coherence Tomography (OCT) and Fluorescein Angiogram (FA) at baseline, and after 1 and 3 months. There were 2 groups, A: Patients with TBRVO; B: Patients with IJRT.
In Group A (5 eyes): 4 eyes (80%), and in Group B (6 eyes): 5 eyes (83.33%) presented an improvement of BCVA at 1 and 3 months that was sustained until the end of study. (P ≤ 0.001) in both groups. At third month, retinal thickness were decreased in most of cases, but this improvement was more important in Group A.
Intravitreal Injection of Bevacizumab is effective in patients with Juxtafoveal Telangiectasias showing an improvement in Visual acuity and reduction of retinal thickness. Effectiveness is similar in both groups. At our knowledge, this is the first report of treatment of Juxtafoveal telangiectasias with Bevacizumab.
This PDF is available to Subscribers Only